Therefore, it is vital to reprogramme M2-like TAMs to M1-like TAMs and inhibit NF-κB pathway in order to reverse the tumor-mediated immunosuppression state and remodel cancer drug resistance. This evidence concerns the gene NFKB1 and cancer.